Modified Monoclonal Antibodies for IP-10 Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for treating inflammatory and autoimmune conditions associated with Interferon gamma inducible protein 10 (IP-10) are not effective in inhibiting its activity, particularly in humans, and there is a need for improved stability and binding affinity.
Innovation Solution
Development of modified monoclonal antibodies that bind to IP-10 with enhanced thermal stability, binding affinity, and functional features, including increased potency in inhibiting IL-6 and IL-12p40 secretion, reducing cytokine levels, and prolonged serum clearance, while minimizing cross-reactivity with other proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to treat IP-10 associated conditions, then treatment can be administered, but the agents are not effective in inhibiting IP-10 activity
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the antibody to achieve higher binding affinity and potency. Specifically, the modified antibody exhibits at least a 50-fold improvement in binding affinity to human IP-10 and at least a 5-fold increase in blocking exogenous IP-10 binding to target cells, directly addressing the ineffectiveness of current agents through precise molecular parameter optimization.
2Stability of the object's composition
If current therapeutic agents are used, then treatment can be provided, but the agents lack optimized physical stability
Solution Approach 1:
The patent improves physical stability through parameter changes in the antibody structure, achieving a first melting temperature (Tm1) of 70.2°C compared to lower stability in conventional agents. This enhanced thermal stability ensures the antibody maintains its functional conformation and binding activity under varying physiological conditions, thereby improving therapeutic reliability.
3Strength
If current agents are used, then treatment is possible, but binding affinity to IP-10 is insufficient
Solution Approach 1:
The patent achieves at least a 50-fold improvement in binding affinity to human IP-10 through modified amino acid sequences in the antibody. This enhanced strength of binding directly extends the duration of action, as the high-affinity interaction ensures prolonged occupancy of the IP-10 target, reducing the frequency of dosing required and extending therapeutic effect.
4Reliability
If current agents are used, then treatment can be administered, but cross-reactivity with other proteins occurs
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the antibody, particularly the complementarity-determining regions (CDRs), to enhance specificity for human IP-10. The modified antibody exhibits at least a 150-fold greater potency in PK/PD modeling and lacks substantial cross-reactivity with human MIG, human ITAC, or mouse IP-10, demonstrating that localized optimization of binding interfaces improves specificity while maintaining therapeutic effectiveness.
Data Source
AI summary
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.